ライフサイエンスコーパス: local treatment

1 v. administration versus regional disease by local treatment.

2 e PTLDs and limited disease may benefit from local treatment.

3 y useful information for determining optimal local treatment.

4 No adjuvant therapy was administered after local treatment.

5 th boost to the tumour bed) or to no further local treatment.

6 and 216 patients (87.8%) received definitive local treatment.

7 th more severe adverse effects compared with local treatment.

8 diagnosis or receiving radiotherapy alone as local treatment.

9 astasectomy, radiotherapy modalities, and no local treatment.

10 er TKI treatment alone or when combined with local treatment.

11 TKI treatment alone and 28 had also received local treatment.

12 ding to stage; 8% of patients had additional local treatments.

13 s (91%) and 6 eyes (50%) received additional local treatments.

14 Among the 28 patients in CR after TKI plus local treatment, 25 patients stopped treatment, and 12 o

15 n therapy (19), radiation therapy (6), or no local treatment (5).

16 Moreover, although gentamicin local treatment alone showed poor efficacy in a clinical

17 e-125 ((125)I) seeds as a safe and effective local treatment alternative.

18 Therapy included local treatment and injection of intraarterial vasodilat

19 men with nonmetastatic PCa who had received local treatment and were recently found to have an incre

20 tic axillary disease may not require further local treatment and whether surgery or radiotherapy is e

21 espect to patient and tumor characteristics, local treatment, and response to chemotherapy.

22 as poor, and efforts to identify the optimal local treatment approach for such patients are warranted

23 Local treatment associating steroids and estrogen seemed

24 An alternative is local treatment at satellite facilities where wastewater

25 how with a fibrosarcoma model Ag104L(d) that local treatment can generate plenty of tumor-specific CT

26 24 types of local treatment comparison were identified.

27 Local treatment consisted of surgery (7 patients), surge

28 Local treatment-emergent adverse events occurred in 7 pa

29 Instrumental variable models of local treatment environment (to control for confounding

30 e variables and clinical prognosticators for local treatment failure (LTF), OS, and DM.

31 The rate of local treatment failure and occurrence of distant metast

32 lation of liver metastases are predictors of local treatment failure at 1 y.

33 There was no case of local treatment failure during a mean follow-up of 21.5

34 There was no case of local treatment failure during follow-up in this series.

35 resolution of targeted FDG avidity, with no local treatment failure during short follow-up (56 days)

36 in eye plaque therapy and may help to reduce local treatment failure in choroidal melanoma.

37 for a new gene expression-based biomarker of local treatment failure in HNSCC.

38 improve early recognition and management of local treatment failure in such patients.

39 The cumulative 2-year Kaplan-Meier rate of local treatment failure in the cohort was statistically

40 h endophthalmitis, orbital dissemination, or local treatment failure in this series, and post-brachyt

41 Further improvement in reducing local treatment failure is likely to have the greatest i

42 Local treatment failure was a relatively infrequent even

43 were endophthalmitis, orbital dissemination, local treatment failure, rhegmatogenous retinal detachme

44 res understanding of factors associated with local treatment failure.

45 specific immune responses may play a role in local treatment failure.

46 e endophthalmitis, orbital dissemination, or local treatment failure.

47 is highly radioresistant, often resulting in local treatment failure.

48 There were fewer local treatment failures in arm A than in arm B; salvage

49 There were five local treatment failures, all of which were in field.

50 veloping LR and its impact on survival after local treatment for DCIS.

51 We use both systemic and local treatment for extramedullary relapse, mainly repre

52 All patients received the same local treatment for genital lesions.

53 the use of sucrose octasulfate dressing as a local treatment for neuroischaemic diabetic foot ulcers.

54 Local treatment for such lesions is in its infancy and l

55 Fourteen of these twenty patients received local treatment for symptomatic intestinal metastases.

56 e-specific antigen (PSA) after their primary local treatments for PC.

57 subgroups of men experiencing failure after local treatments for PC.

58 lantation via a local delivery catheter, (2) local treatment group receiving one-time treatment (200

59 These findings suggest that national and local treatment guidelines need to be reviewed urgently.

60 All these local treatments have been refined, resulting in compara

61 rrence, with the aim of completing the whole local treatment in one sitting.

62 rapeutic potential of PUMA gene therapy as a local treatment in various forms of arthritis in which a

63 We evaluated 2 local treatments, intralesional (IL) Sb and cryotherapy,

64 y for confining HNSCC invasion to facilitate local treatment is limited.

65 jor procedure in case of failure of previous local treatment, leads to high success rates.

66 r malignancies has indicated that aggressive local treatment (LT), even in the presence of metastatic

67 atients with recurrent prostate cancer after local treatment make up a heterogeneous population for w

68 Utilization of other local treatment modalities, such as radiation therapy an

69 CC clinical stage, biopsy Gleason score, and local treatment modality.

70 of arthritis (antigen-induced arthritis) for local treatment of arthritis with recombinant mouse TSG-

71 dence that CPE may be uniquely suited to the local treatment of brain metastasis.

72 o toxicity, it may provide a vehicle for the local treatment of cancer.

73 Photodynamic therapy (PDT) is a local treatment of cancers.

74 aocular ganciclovir implant is effective for local treatment of cytomegalovirus retinitis in patients

75 ese techniques has opened a new road for the local treatment of esophageal HGD and IMC.

76 mising perivascular drug delivery design for local treatment of hemodialysis AV graft hyperplasia and

77 ODE-Bn-PMEG is a promising candidate for the local treatment of HPV-16 and HPV-18 and other high-risk

78 potential of FOLH1/GCPII inhibitors for the local treatment of IBD.

79 eview of all types of comparative studies on local treatment of metastases from renal cell carcinoma

80 Local treatment of metastases such as metastasectomy or

81 The local treatment of metastatic disease has been promoted

82 Importantly, local treatment of NHPs with Cp40 inhibited ligature-ind

83 has been approved recently in Europe for the local treatment of patients with cutaneous metastasis.

84 n (36+, 35+, 26+, 24+, and 23+ months) after local treatment of progressive metastases.

85 There has been a gradual migration in the local treatment of soft tissue sarcomas from amputation

86 Systemic treatment of zebrafish or local treatment of the chick chorioallantoic membrane wi

87 Local treatment of the DRG axons with NGF or BDNF increa

88 Local treatment of vulnerable plaques by percutaneous co

89 We also analyzed the effect of local treatment on survival among older men with high-ri

90 fe, minimally invasive, and highly effective local treatment option for pediatric patients with inope

91 ecently come to the forefront as a potential local treatment option for women with breast cancer.

92 describes neoadjuvant hormonal therapy, new local treatment options (including three-dimensional con

93 Both RFA and SBRT are effective local treatment options for inoperable HCC.

94 In addition, the pharmacological and local treatment options will be reviewed.

95 metastases has expanded recently and adds to local treatment options.

96 42-3p inhibition, either by a preventive and local treatment or by a therapeutic and systemic strateg

97 who were treated had a complete response to local treatment or hormonal therapy (or both), 16 died o

98 made by some groups to explore ways in which local treatment, particularly radiotherapy, can be omitt

99 There were geographic variations in initial local treatment patterns and in post-treatment costs.

100 The mean (SD) cost of local treatment per patient per day varied between euro2

101 ized as local only, primary ADT monotherapy, local treatment plus ADT, and watchful waiting/active su

102 reference of noninvestigational treatment or local treatment, poor performance status or other reason

103 orward movement of the cell nucleus, whereas local treatment posterior to the nucleus caused reversal

104 the questionnaire analysis vary depending on local treatment practices, from a minimum of &OV0556;33,

105 as predictive of outcome and correlated with local treatment received.

106 mined through data linkage with national and local treatment registers, medical record review, interv

107 Local treatment should be interrupted according to the h

108 tion through systemic improvement and myriad local treatments, some not ordinarily used by the ophtha

109 s add to the evidence questioning aggressive local treatment strategies in men with low-risk prostate

110 Therefore, alternate local treatment strategies should be considered for olde

111 Differences between EFS and OS reflected local treatment strategy and successful re-treatment for

112 Despite local treatment success, systemic prognosis remained gua

113 y, steroids, and bisphosphonates) as well as local treatments (such as surgery, nerve blocks, and ext

114 e breast cancer for which they had undergone local treatment (surgery with or without radiotherapy) a

115 unitinib or sorafenib), either alone or with local treatment (surgery, radiotherapy, or radiofrequenc

116 Local treatment, targeted at inhibition of interleukins

117 Differences in local treatment that substantially affect local recurren

118 In early breast cancer, variations in local treatment that substantially affect the risk of lo

119 oncolytic viruses has been demonstrated for local treatment, the ability to induce immune-mediated r

120 Although radiation is primarily a local treatment, the exquisite radiosensitivity of lymph

121 nvestigate the benefits and harms of various local treatments, we did a systematic review of all type

122 pond adequately to systemic chemotherapy and local treatment where appropriate or because of a new re

123 Local treatment, whether irradiation or resection, or bo

124 s tissue at the fracture site was rescued by local treatment with a Wingless-type MMTV integration si

125 These results collectively show that local treatment with Ad5-mTRAIL and CpG ODN can augment

126 However, local treatment with an Ab to TGF-beta led to both a dec

127 appears to be indirect, as it was reduced by local treatment with anti-TNF-alpha antibody, IL-1-recep

128 These data demonstrate that early, local treatment with CXC chemokines enhances neutrophil

129 Furthermore, local treatment with IL-10 promoted lymphangiogenesis an

130 Local treatment with IL-12 inoculated into the parasitiz

131 host response to this infection and whether local treatment with IL-12 or gene transfer of IL-12 cou

132 Local treatment with modest doses of 65828 significantly

133 Local treatment with PRL or increasing PRL circulating l

134 Local treatment with selected TLR ligands or bacteria su

135 Consistent with this, local treatment with sFRP5 in mice subjected to ligature

136 After definitive local treatment with surgery, radiotherapy, or both, pat

137 determined by intrahepatic HCC progression, local treatment with TACE may result in improved OS, alt

138 could be transiently reverted by systemic or local treatment with the TRPA1 antagonist HC-030031.

139 mouse models of periodontitis, we show that local treatments with a C5aR antagonist inhibited period

140 ategies emerge: global preventive treatment, local treatment within a neighborhood of certain size an

141 While local treatment would avoid the systemic treatment side-